SpectraScience: Innovations in Cancer Detection
SpectraScience has developed patented platform technology that diagnoses colorectal cancer, which has a market size of $1, 442.6 million.
SpectraScience has developed patented platform technology that diagnoses colorectal cancer, which has a market size of $1, 442.6 million.
DesignMedix places great emphasis on tackling problems of drug resistant diseases, such as malaria, bacteria, and cancer.
BioLife Solutions has a strong interest in target markets: regenerative medicine, biobanking, and drug discovery.
Avantis Medical Systems is company that is tapping into large Endoscope market which has 30 million colonoscopies globally and 15 million in the US alone.
OneMedForum announced today that it has assembled two panels featuring early entrants in the emerging areas of crowdfunding and online investment banking in healthcare. Panelists […]
Monteris Medical is a neurosurgical company with a focus on creating unique and innovative technology to treat serious brain disorders. Their flagship product, the Neuroblate Thermal Therapy System creates minimally invasive treatments for soft tissue and brain lesions
Diagnovus is a specialized molecular diagnostic company, focused on delivering personalized diagnostic information and services to physicians treating patients suffering from rare, orphan and less frequent diseases. We are privileged for the opportunity to serve patients and the physicians treating them.
Regenesis Biomedical’s Provant Therapy System is FDA approved for the palliative treatment of post-operative pain and edema in superficial soft tissue. Post surgery, many tissues may be moved around or inflamed, but Provant helps reduce the pain by inducing endogenous opioids. This prescription only device exposes tissue to electromagnetic energy using an optimized energy pulse.
Preliminary data in preclinical models of severe complex wounds suggests that human VSELs™ (very small embryonic like stem cells) accelerates wound healing. NeoStem hopes to advance into early clinical studies to assess therapeutic potential of VSEL technology.
Early results for the new flu drug FluCide® found to be safe in a non-GLP small animal safety/ toxicology study. These preliminary results support the company’s earlier reports of the FluCide® drug being effective in animal models of different influenza A virus strains. NanoViricides is also developing drugs against HIV/AIDS (HivCide™-I), Dengue (DengueCide™-I), and External Eye Viral disease (EKC-Cide™-I), amongst other viral diseases.
Copyright © 2024 | WordPress Theme by MH Themes